TOPLINE: In patients with non-ST-elevation myocardial infarction (NSTEMI) and frailty, an initial invasive strategy caused early harm followed by late benefit, resulting in a neutral effect […]

Cervical manipulations have been associated with vascular complications. While the incidence of carotid dissections does not seem to have increased, the question remains open for vertebral […]

A recent study linking a niacin derivative to an increased risk for cardiovascular events has raised questions about the safety of this B vitamin, which is […]

TOPLINE: Cardiopulmonary exercise testing may be useful in characterizing distinct patterns of functional impairment in patients with transthyretin amyloidosis (ATTR), a multisystem, life-threatening disease resulting from […]

TOPLINE: Methylphenidate was associated with a small increased risk for cardiovascular events in individuals taking the drug for more than 6 months in a new cohort […]

A new study has highlighted the risks for syncope and bradycardia as potential side effects with anti-arrhythmic drugs when used for the treatment of atrial fibrillation […]

A paclitaxel-coated balloon, Agent DCB (Boston Scientific), was superior to an uncoated balloon for treating coronary in-stent restenosis in patients undergoing percutaneous coronary intervention (PCI), in […]

Silence Therapeutics announced positive topline 36-week data from its ongoing phase 2 study of zerlasiran, a long-acting agent directed at lowering Lp(a) levels.  In a statement, […]

The American College of Cardiology has published a new update to its consensus decision pathway for the treatment of heart failure with reduced ejection fraction (HFrEF). […]